In a report released on April 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on PureTech Health (PRTC – Research Report). The ...

Fintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a ...

In a report released on April 4, Michael Cherny from Leerink Partners maintained a Hold rating on Medpace Holdings (MEDP – Research Report).

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

To make sense of the stock selloff that started late last week, Endpoints News’ Max Bayer and Drew Armstrong spoke to Leerink ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective dropped by Leerink Partners from $19.00 to $18.00 ...

today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...